HONG KONG – Suzhou-based Alphamab Oncology Co. Ltd. pocketed $60 million in a series B financing to advance into the clinic with its potentially first-in-class PD-L1/CTLA4 bispecific antibody, KN-046, and to prepare for commercialization of its more advanced product, subcutaneous PD-L1 antibody KN-035 (envafolimab). Read More
Scientists have discovered a pair of gut microbial enzymes that worked in tandem to convert blood cells of the type A to those of type O by removing the surface molecule alpha-1,3-linked-N-acetylgalactosamine (GalNAc) from the surface of red blood cells. Read More
PHILADELPHIA –The escalating trade war between the United States and China dominated most of the discussion during the China Summit meeting at the Biotechnology Innovation Organization' (BIO) international convention. Read More
HONG KONG – Aiming to expand its market in greater China, Cstone Pharmaceuticals Co. Ltd. submitted a new drug application (NDA) for Tibsovo (ivosidenib) to the Taiwan Food and Drug Administration (TFDA), seeking approval of the first drug to treat adults with relapsed or refractory (r/r) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. Read More
PERTH, Australia – After a AU$2 million (US$1.4 million) capital raise in April, Perth-headquartered Pharmaust Ltd. will advance its lead compound monepantel into phase I trials in humans. Read More
HONG KONG – New results from a study of South Korean company Qurient Co. Ltd.'s orally available antibiotic, telacebec, suggest it is moving closer to offering a new therapeutic option for people with multidrug-resistant tuberculosis (MDR-TB). Read More
PHILADELPHIA – Shanghai-based Epimab Biotherapeutics Inc. raised $74 million in a series B round to advance its phase I/II lead candidate, EMB-01, and expand its pipeline into immuno-oncology. Read More
Peptidream Inc., of Kanagawa, Japan, said it inked a deal with Seattle-based Pharmain Corp. to investigate the use of the latter's drug carrier and delivery PGC (protected graft co-polymer) technology in combination with Peptidream's peptide discovery and development programs. Read More
Eisai Inc., of Woodcliff Lake, N.J., the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co. Ltd., appointed Patrick Coyle vice president and chief financial officer to lead Eisai's financial operations in the United States and Canada. Read More
